INDICATIONS: TREATMENT FOR STAGE I, II & III
(A&B) BREAST CANCERS
Combination chemotherapy with cyclophosphamide
(Cytoxan) and doxorubicin (adriamycin); also
|These drugs have been
approved by the FDA (Food and Drug
Administration) for the treatment of breast
Cyclophosphamide 600 mg/M2, Adriamycin 60 mg/M2
TIMING: Given once every 21 days for 4 treatments
decrease in blood cells, especially white
cells (neutropenia) but also red cells
(anemia) and or platelets
possible nausea and vomiting (which may
be decreased or prevented with
medications); diarrhea; mouth sores;
severe hair loss; dry skin, nail thinning
cytoxan may cause irritation to the
kidneys or bladder.
cytoxan may cause damage to the ovaries
of premenopausal women. This may lead to
temporary or permanent infertility.
Patients may also develop an early
adriamycin may cause a weakening of the
heart muscle. In severe cases this may
result in congestive heart failure. This
may occur in less than 1% of patients
receiving standard doses.
some patients complain of a decrease in
their ability to concentrate and/or
remember, which improves on completion of
some patients complain of taste changes
and/or lack of appetite.
1997 - TransMed Network